University of California, Berkeley
berkeley.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
106
Active
17
Phase 3
4
Total enrollment
239,962
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Varenicline 0.03Mg/Spray Nasal Soln | — | — | — | — | — | 1 | |
| Psilocybin | — | — | — | — | — | 2 |
Next readouts
- 2026-12-30
- 2026-12-31
- 2028-12-31
Top conditions
- Sleep Disorder7
- Circadian Dysregulation7
- Diarrhea6
- Dementia5
- Mild Cognitive Impairment5
- Alzheimer Disease5
- Obesity4
- Overweight4
Frequently asked questions about University of California, Berkeley
- How many clinical trials does University of California, Berkeley have on ClinicalTrials.gov?
- University of California, Berkeley is listed as the lead sponsor on 106 clinical trials in ClinicalTrials.gov, 17 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of California, Berkeley's trials are in Phase 3?
- 4 of University of California, Berkeley's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does University of California, Berkeley focus on?
- University of California, Berkeley's most-studied conditions on ClinicalTrials.gov are Sleep Disorder, Circadian Dysregulation, Diarrhea, Dementia, Mild Cognitive Impairment.
- When are University of California, Berkeley's next clinical trial readouts?
- University of California, Berkeley has 3 upcoming primary-completion readouts tracked here; the soonest is “Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults”, expected around 2026-12-30.